XERS insider filings
Xeris Biopharma Holdings, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-06. Screen XERS transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 13 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 11 legs across 11 filings by 3 insiders — 168,332 shares, $1,678,894 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 2.
- Largest priced transaction: sale of 25,000 shares @ $12.49 ($312,215) by McCulloch Kevin, filed 2026-11-06.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| McCulloch Kevin — See Remarks | 5 | — | 5 legs · 95,000 sh · $984,130 | — |
| Hecht Beth — See Remarks | 3 | — | 3 legs · 58,332 sh · $554,054 | — |
| Pieper Steven — See Remarks | 3 | — | 3 legs · 15,000 sh · $140,710 | — |
| Taddese Menassie — Director | 2 | — | — | 2 |
Recent insider filings — Xeris Biopharma Holdings, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-06 | 4 | McCulloch Kevin — See Remarks | Sale (S): 25,000 @ $12.49 | EDGAR |
| 2026-11-04 | 4 | McCulloch Kevin — See Remarks | Sale (S): 15,000 @ $10.23 | EDGAR |
| 2026-11-04 | 4 | Hecht Beth — See Remarks | Sale (S): 25,000 @ $10.23 | EDGAR |
| 2026-11-04 | 4 | Pieper Steven — See Remarks | Sale (S): 5,000 @ $10.23 | EDGAR |
| 2026-11-04 | 3 | Taddese Menassie — Director | Holdings only — no transactions reported | EDGAR |
| 2026-11-04 | 4 | Taddese Menassie — Director | Grant/award (A): 22,365 @ $0 · Grant/award (A): 31,499 (derivative) @ $10.17 | EDGAR |
| 2026-10-02 | 4 | Hecht Beth — See Remarks | Sale (S): 16,666 @ $9.41 | EDGAR |
| 2026-10-02 | 4 | McCulloch Kevin — See Remarks | Sale (S): 15,000 @ $9.41 | EDGAR |
| 2026-10-02 | 4 | Pieper Steven — See Remarks | Sale (S): 5,000 @ $9.41 | EDGAR |
| 2026-09-29 | 4 | McCulloch Kevin — See Remarks | Sale (S): 25,000 @ $10 | EDGAR |
| 2026-09-01 | 4 | Pieper Steven — See Remarks | Sale (S): 5,000 @ $8.50 | EDGAR |
| 2026-09-01 | 4 | Hecht Beth — See Remarks | Sale (S): 16,666 @ $8.49 | EDGAR |
| 2026-09-01 | 4 | McCulloch Kevin — See Remarks | Sale (S): 15,000 @ $8.49 | EDGAR |
| 2026-08-21 | 4 | Shannon John Patrick Jr — See Remarks, Director | Tax withholding (F): 36,645 @ $8.08 | EDGAR |
| 2026-08-21 | 4 | McCulloch Kevin — See Remarks | Tax withholding (F): 21,918 @ $8.08 | EDGAR |
| 2026-08-12 | 4 | Pieper Steven — See Remarks | Sale (S): 5,000 @ $8.50 | EDGAR |
| 2026-08-04 | 4 | McCulloch Kevin — See Remarks | Sale (S): 15,000 @ $8.02 | EDGAR |
| 2026-08-04 | 4 | Hecht Beth — See Remarks | Sale (S): 16,666 @ $8.01 | EDGAR |
| 2026-07-07 | 4 | Pieper Steven — See Remarks | Sale (S): 17,400 @ $8.50 · Sale (S): 27,600 @ $8.52 | EDGAR |
| 2026-07-02 | 4 | McCulloch Kevin — See Remarks | Sale (S): 90,000 @ $8.03 | EDGAR |
| 2026-07-02 | 4 | KREHER NERISSA — Director | Grant/award (A): 33,582 @ $0 · Grant/award (A): 37,910 (derivative) @ $8 | EDGAR |
| 2026-07-02 | 4 | Hecht Beth — See Remarks | Sale (S): 16,666 @ $8.03 | EDGAR |
| 2026-06-05 | 4 | Brady James Aloysius — Director | Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15 | EDGAR |
| 2026-06-05 | 4 | HALKUFF DAWN — Director | Sale (S): 20,000 @ $6.09 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15 | EDGAR |
| 2026-06-05 | 4 | BORMANN-KENNEDY BARBARA-JEAN ANNE — Director | Sale (S): 16,000 @ $6.09 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15 | EDGAR |
| 2026-06-05 | 4 | Kong Garheng — Director | Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15 | EDGAR |
| 2026-06-05 | 4 | JOHNSON JOHN — Director | Sale (S): 15,000 @ $6.09 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15 | EDGAR |
| 2026-06-05 | 4 | PERSKY MARLA — Director | Sale (S): 15,500 @ $5.90 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15 | EDGAR |
| 2026-06-02 | 4 | Hecht Beth — See Remarks | Sale (S): 16,667 @ $6.06 | EDGAR |
| 2026-05-01 | 4 | Hecht Beth — See Remarks | Sale (S): 16,667 @ $6.23 | EDGAR |
| 2026-04-03 | 4 | Hecht Beth — See Remarks | Sale (S): 16,667 @ $5.99 | EDGAR |
| 2026-04-01 | 4 | Brady James Aloysius — Director | Sale (S): 10,834 @ $5.54 | EDGAR |
| 2026-03-16 | 4 | McCulloch Kevin — See Remarks | Option exercise (M): 48,894 @ $4.09 · Option exercise (M): 4 @ $3.94 · Option exercise (M): 48,894 (derivative) @ $4.09 · Option exercise (M): 4 (derivative) @ $3.94 | EDGAR |
| 2026-03-05 | 4 | Pieper Steven — See Remarks | Option exercise (M): 27,891 @ $4.09 · Option exercise (M): 14,036 @ $5.93 · Option exercise (M): 27,891 (derivative) @ $0 · Option exercise (M): 14,036 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Hecht Beth — See Remarks | Sale (S): 16,567 @ $6.24 · Sale (S): 100 @ $7.06 | EDGAR |
| 2026-02-25 | 4 | Nguyen Anh Tu — See Remarks | Tax withholding (F): 29,300 @ $6.88 | EDGAR |
| 2026-02-02 | 4 | Nguyen Anh Tu — See Remarks | Grant/award (A): 121,293 @ $0 · Grant/award (A): 162,162 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | McCulloch Kevin — See Remarks | Grant/award (A): 168,463 @ $0 · Tax withholding (F): 68,454 @ $7.36 · Tax withholding (F): 30,289 @ $7.36 · Tax withholding (F): 27,319 @ $7.36 · Grant/award (A): 225,225 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Pieper Steven — See Remarks | Grant/award (A): 154,986 @ $0 · Tax withholding (F): 111,765 @ $7.36 · Tax withholding (F): 66,450 @ $7.36 · Tax withholding (F): 27,319 @ $7.36 · Grant/award (A): 207,207 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Hecht Beth — See Remarks | Grant/award (A): 121,293 @ $0 · Tax withholding (F): 98,375 @ $7.36 · Tax withholding (F): 46,914 @ $7.36 · Tax withholding (F): 24,266 @ $7.36 · Sale (S): 16,667 @ $7.45 · Grant/award (A): 162,162 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Shannon John Patrick Jr — See Remarks, Director | Grant/award (A): 478,436 @ $0 · Tax withholding (F): 118,134 @ $7.36 · Tax withholding (F): 111,621 @ $7.36 · Tax withholding (F): 110,750 @ $7.36 · Grant/award (A): 639,639 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | McCulloch Kevin — See Remarks | Sale (S): 15,000 @ $8 | EDGAR |
| 2026-01-06 | 4 | Shannon John Patrick Jr — See Remarks, Director | Sale (S): 24,907 @ $7.08 · Option exercise (M): 64,265 @ $1.55 · Option exercise (M): 25,136 @ $1.55 · Option exercise (M): 2,900 @ $3.94 · Option exercise (M): 64,265 (derivative) @ $0 · Option exercise (M): 25,136 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-05 | 4 | Hecht Beth — See Remarks | Sale (S): 16,667 @ $7.43 | EDGAR |
| 2025-12-19 | 4 | JOHNSON JOHN — Director | Sale (S): 135,400 @ $7.22 | EDGAR |
| 2025-12-15 | 4 | BORMANN-KENNEDY BARBARA-JEAN ANNE — Director | Sale (S): 15,000 @ $7.09 | EDGAR |
| 2025-12-02 | 4 | Hecht Beth — See Remarks | Sale (S): 16,667 @ $7.01 | EDGAR |
| 2025-11-17 | 4 | Shannon John Patrick Jr — See Remarks, Director | Option exercise (M): 8,970 @ $1.55 · Sale (S): 23,242 @ $7.46 · Option exercise (M): 87,100 @ $1.55 · Option exercise (M): 8,970 (derivative) @ $0 · Option exercise (M): 87,100 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Hecht Beth — See Remarks | Sale (S): 16,667 @ $7.40 | EDGAR |
| 2025-10-03 | 4 | McCulloch Kevin — See Remarks | Tax withholding (F): 733 @ $8.31 | EDGAR |
Recent 8-K events — Xeris Biopharma Holdings, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-14 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-17 | 8-K | 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events | EDGAR |
| 2026-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=XERS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs